This is most definitely a bullish presentation by Nigel . Great to hear that he is liking what he seeing regarding revenue to come this quarter so this could be gaining momentum. G-BA updates to come in the next quarter or so , R & D refund expected to be around $ 1 million and they have enough funds until end of next calendar year and by then if revenue does increase as expected , further expansion into markets, approvals , clinical trial updates , TGA , FDA , updates the stock price should reflect this. Even if funds are required by the end of next calendar year the stock price is going to be much higher.
The market cap under $ 20 million is going to look ludicrous soon. I have been and plan on continuing to top up when possible . It is time to look forward investors and not behind, what is done is done. This sector is slow and brutal but a turnaround is looking far better right now .
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)